These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15893813)

  • 1. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
    Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk.
    Salinas CA; Austin MA; Ostrander EO; Stanford JL
    Prostate; 2005 Sep; 65(1):58-65. PubMed ID: 15810021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci.
    Xue W; Irvine RA; Yu MC; Ross RK; Coetzee GA; Ingles SA
    Cancer Res; 2000 Feb; 60(4):839-41. PubMed ID: 10706090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
    Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Carvalho R; Lopes C
    Prostate; 2002 Sep; 53(1):88-94. PubMed ID: 12210484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
    Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
    Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
    Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
    Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.
    Nam RK; Elhaji Y; Krahn MD; Hakimi J; Ho M; Chu W; Sweet J; Trachtenberg J; Jewett MA; Narod SA
    J Urol; 2000 Aug; 164(2):567-72. PubMed ID: 10893645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
    Chiang CH; Chen KK; Chang LS; Hong CJ
    J Urol; 2004 Apr; 171(4):1529-32. PubMed ID: 15017213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.